Variation

[키워드] A1AT acute respiratory syndrome Administered Affect affecting age Alpha alpha-1-antitrypsin antithrombin III antitrypsin Antiviral antiviral drug antiviral intervention approach asymptomatic infection asymptomatic infections ATIII can be used cellular cellular protease ciliated cleavage club Comorbidities Comorbidity complex coronavirus disease Coronavirus disease 2019 COVID-19 deficiency determinant determinants disease disease severity Donor door expression expression level Factor Genetic Genetic variation Genetic variations goblet cells highlight Host human donors identification identify identity immune response individual Infection inhibitor inhibitors less lung cell mechanism mechanism of action outcome PAI1 Patient patients plasminogen activator inhibitor 1 Potential potential treatments primary cell primary cells reduce reducing regulate restrict risk risk factor Risk factors SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 susceptibility Serine serine protease serine protease inhibitor serine protease inhibitors serpin serpin. SERPINA1 SERPINE1 SERPINE2 serpins Severe acute respiratory syndrome severe COVID-19 severe infections Sex Single-cell RNA sequencing Spike protein susceptibility susceptible Symptom target cells TMPRSS2 Treatment Usage Variation viral burden viral entry viral spike protein
[DOI] 10.1128/mbio.00892-22 PMC 바로가기 [Article Type] Article